Eurobio Scientific: FIRST HALF TURNOVER REACHES € 95.7 MILLION, A 54% INCREASE
26 Luglio 2021 - 5:45PM
Eurobio Scientific: FIRST HALF TURNOVER REACHES € 95.7 MILLION, A
54% INCREASE
FIRST HALF TURNOVER REACHES € 95.7
MILLION, A 54% INCREASE
- Strong growth in traditional activities excluding COVID : + 31%
at € 40.9 million
- Extension of the installed instrument park
- Continuation of the proprietary products development
strategy
Paris,
July
26, 2021 –
5:45
pm
Eurobio Scientific
(FR0013240934, ALERS, PEA-PME eligible), a leading French
group in in vitro medical diagnostics and life sciences, today
presents its consolidated half-year turnover as at June 30,
2021.
New semester of strong
growth
Eurobio Scientific recorded a turnover of € 95.7
million in the first half of 2021, up 54% compared to the first
half of 2020. This performance reflects:- Continued sales linked to
the diagnosis of COVID (€ 54.8 million, or 57% of turnover);
- Strong growth in traditional activities,
excluding COVID (€ 40.9 million, or 43% of turnover).
in M€ |
H1 2021 |
H1 2020 |
var. |
COVID |
54,8 |
31,0 |
+77% |
Excluding COVID |
40,9 |
31,1 |
+31% |
Total |
95,7 |
62,2 |
+54% |
not audited |
|
|
|
|
Maintaining a
high market share in COVID
diagnostics
During the first half of the year, the Group
continued to enrich its COVID diagnostic offering with PCR, antigen
and self-tests. In line with its strategy focused on increasing its
share of proprietary products, almost all of these new tests were
developed in-house (EBX and EBS ranges). For example, Eurobio
Scientific launched at the end of May the first test (EBX-046) able
to simultaneously detect the virus and characterize mutations of
interest ("variants").Compared to the second half of 2020, COVID
revenue is down (€ 54.8m vs € 86m) under the cross effect of an
anticipated drop in selling prices and a market switch in favor of
pharmacy networks, in which the Group has limited marketing
presence.
Thanks to its range of reagents and its
penetration of large private and hospital laboratories, Eurobio
Scientific remains one of the main French players in the diagnosis
of COVID and has continued to increase its park of installed
instruments. The majority of these instruments are “universal” and
accommodate both COVID tests and other infectious diseases tests,
in particular the Group's proprietary EBX range.
Strong growth in revenues excluding
COVID at + 31% (+ 23% organically)
The increased visibility of Eurobio Scientific,
in France and internationally, the extension of its customer
portfolio and its park of instruments, and the activation of
synergies with its foreign affiliates (TECOmedical and Pathway
Diagnostic) have fostered strong growth in non-COVID sales. These
amounted to € 40.9 million during the first semester, up 31%. On a
like-for-like basis (excluding TECOmedical sales), growth remains
strong, at + 23%.
The strong momentum initiated in the context of
the health crisis, combined with the recurrence of sales inherent
in Eurobio Scientific's business model, enabled the Group to
accelerate the development of its traditional activities. At the
same time, the synergies implemented with the recently acquired
international subsidiaries continued, and their sales represented €
7.5 million over the half-year. In particular, the COVID crisis
made it possible to quickly set up infectious disease activities in
subsidiaries where they were not previously present.
Significant financial resources to
deploy the strategy
With gross cash currently exceeding € 80
million, Eurobio Scientific has very significant financial
resources to continue to deploy its strategy, which is mainly
focused on increasing the share of proprietary products. This
involves financing internal developments or targeted
acquisitions.
At the same time, the Group continues to
selectively develop its distribution portfolio. Eurobio Scientific
has thus renewed its non-exclusive partnership with the Korean
company Seegene this semester, at least until 2023, and signed
distribution partnerships in new areas, for example with the Alcor
and BenQ laboratories.
On the basis of the new dimension acquired in
2020, Eurobio Scientific has all the assets to continue to meet the
needs of laboratories, in France and in the rest of Europe, through
the deployment of an extensive offer mixing proprietary and
distribution products.
Next financial meetingHalf-year
results 2021: October 12, 2021, after market close
Disclaimer This press release contains elements
that are not historical facts including, without limitation,
certain statements about future expectations and other
forward-looking statements. Such statements are based on
management’s current views and assumptions and involve known and
unknown risks and uncertainties that could cause actual results,
profitability or events to differ materially from those
anticipated. In addition, Eurobio Scientific, its shareholders, and
its affiliates, directors, officers, advisors and employees have
not verified the accuracy of, and make no representations or
warranties in relation to, statistical data or predictions
contained in this press release that were taken or derived from
third party sources or industry publications. Such statistical data
and predictions are used in this press release for information
purposes only. Finally, this press release may be drafted in the
French and English languages. If both versions are interpreted
differently, the French language version shall prevail.
About Eurobio
ScientificEurobio Scientific is a key player in
the field of specialty in vitro diagnostics. It is involved from
research to manufacturing and commercialization of diagnostic tests
in the fields of transplantation, immunology and infectious
diseases, and sells instruments and products for research
laboratories, including biotechnology and pharmaceutical companies.
Through many partnerships and a strong presence in hospitals,
Eurobio Scientific has established its own distribution network and
a portfolio of proprietary products in the molecular biology field.
The Group has approximately 148 employees and three production
units based in the Paris region, in Germany and in the United
States, and several affiliates based in Dorking UK, Sissach
Switzerland, Bünde Germany and Utrecht in The Netherlands. For more
information, please visit : www.eurobio-scientific.com The company
is publicly listed on the Euronext Growth market in ParisEuronext
Growth BPI Innovation, PEA-PME 150 and Next Biotech indices,
Euronext European Rising Tech label.Symbol: ALERS - ISIN Code:
FR0013240934 - Reuters: ALERS.PA - Bloomberg: ALERS:FP |
Contacts |
Group Eurobio ScientificDenis Fortier, General
ManagerHervé Duchesne de Lamotte, General ManagerTel. +33(0) 1 69
79 64 80 |
CalyptusMathieu Calleux / Gregory BossonInvestors
relationsTel. +33(1) 53 65 68 68
eurobio-scientific@calyptus.net |
- PR_Eurobio Scientific_CA_S1_21_EN
Grafico Azioni Eurobio Scientific (EU:ALERS)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Eurobio Scientific (EU:ALERS)
Storico
Da Apr 2023 a Apr 2024